Parabilis Medicines, Inc. (PBLS)

NASDAQ: PBLS · USD

$28.2

+1.67 (+6.3%)· Recorded snapshot

Market cap	3.5B
Revenue (ttm)	148K
Net income (ttm)	-231.7M
EPS (ttm)	-$23.4
Shares out	123.5M
Volume	1,254,410

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 148K
Net income (ttm): -231.7M
EPS (ttm): -$23.4
Market cap: 3.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All PBLS indicators

Market & fundamental data

Available fields

159

Groups with data

Currency

USD

Showing 159 of 159 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001657677
Company name	Parabilis Medicines, Inc.
Country	United States
Country code	US
CUSIP number	698955101
Earnings date	2026-11-17
Earnings time	bmo
Employees	145
Employees change	0
Employees growth	0%
Enterprise value	$2.4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-07-12
Fiscal year end	December
Founded	2015
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2026-06-10
Is primary listing	Yes
Is SPAC	No
ISIN number	US6989551014
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3.5B
Market cap category	Mid-Cap
Next earnings date	2026-11-17
Options	Yes
Price	$28.18
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	PBLS
U.S. state	Massachusetts
Website	https://parabilismed.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-83.2%
EV/Sales	15,097.42x
FCF / EV yield	-5.03%
FCF yield	-3.4%
Forward EV/Sales	540.58x
Forward P/S	800.23x
P/B ratio	3.13x
P/S ratio	22,348.67x
Price / tangible book value	3.16x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-115,907.43%
Pretax margin	-115,224.32%
Profit per employee	$-1.6M
Revenue per employee	$1,021
ROCE	-15.42%
SBC / revenue	4,445.95%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.2M
Depreciation and amortization	$2.4M
EBIT	$-171.5M
EBITDA	$-169.1M
EPS	$-23.45
FCF per share	$-0.91
Financing cash flow	$1.1B
Free cash flow	$-112.5M
Free cash flow minus SBC	$-119.1M
Gross profit	$-13M
Investing cash flow	$-25.9M
Net borrowing	$-10.6M
Net cash flow	$1B
Net income	$-231.7M
Operating cash flow minus SBC	$-117.9M
Operating income	$-171.5M
Revenue	$148,000
Stock-based compensation	$6.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	16.24
Book value per share	$8.48
Debt / equity	0.05
Interest coverage	-139.58
Long-term assets	$49.9M
Long-term liabilities	$64.7M
Net cash (debt)	$1.1B
Net cash / market cap	32.45%
Net debt / equity	-1.02
Piotroski F-Score	1
Property, plant and equipment	$42.4M
Shareholders' equity	$1B
Tangible book value	$1B
Tangible book value per share	$8.48
Total assets	$1.2B
Total cash	$1.1B
Total debt	$47.5M
Total liabilities	$127.5M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$1.1B
Current liabilities	$62.8M
Current ratio	17.91
Net working capital	$-44.2M
Quick ratio	17.83
Working capital	$1.1B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	6.3%
1M price change	-12.63%
1M total return	-12.63%
1W price change	0.66%
1W total return	0.66%
20-day SMA	$27.18
3M price change	-14.33%
3M total return	-14.33%
50-day SMA	$33.42
52-week high	$42.49
52-week high date	2026-09-18
52-week low	$22.66
52-week low date	2026-10-16
All-time high	$42.49
All-time high date	2026-09-18
All-time low	$22.66
All-time low date	2026-10-16
Average true range (ATR)	$2.54
Average volume	1.2M
Beta (1Y)	-0.09
Change from 52-week high	-33.67%
Change from 52-week low	24.36%
Change from all-time high	-35.84%
Change from all-time low	20.3%
Change from open	6.3%
Day's gap	0%
Dollar volume	$35.3M
High price	$28.23
Low price	$26.51
Monthly RSI	0
Open price	$26.51
Position in 52-week range	97.09%
Premarket change	1.4%
Premarket close	$26.51
Premarket price	$26.88
Premarket volume	189
Previous close	$26.51
Price vs 20-day SMA	0.3%
Price vs 50-day SMA	-18.42%
Relative volume	1.06
Return from IPO open	-19.72%
Return from IPO price	33.88%
RSI	45.43
Sharpe ratio	-0.2
Sortino ratio	-0.2
Volume	1.3M
Weekly RSI	49.26

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	82.1M
Float percentage	66.44%
Shares change (QoQ)	816.33%
Shares held by insiders	0.1%
Shares held by institutions	53.88%
Shares outstanding	123.5M
Short % of float	11.27%
Short % of shares	7.49%
Short ratio	7 days

Deeper analysis on PBLS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this PBLS report

Is a complete PBLS research report available?

No complete published report is available for Parabilis Medicines, Inc. (PBLS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Parabilis Medicines, Inc. (PBLS)

Price

Financial snapshot

Fair-value bridge

Latest news · PBLS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PBLS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on PBLS

Frequently asked questions